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Pyrrolidinedithiocarbamate (PDTC) enhanced the activity of 5-fluorouracil (5-FU) in a colorectal cancer xenograft model.
Pyrrolidinedithiocarbamate also reduced gastrointestinal toxicity associated with 5-FU therapy in large but not small bowel. We
sought to clarify the basis of this differential enteric toxicity. Apoptosis and mitosis were assessed on a cell positional basis in small and
large intestinal crypts of p53 wild-type (þ/þ) and p53 null ( / ) mice 6, 12, 24, 36, 48 and 72h after the administration of high
(200mgkg
 1) or low (40mgkg
 1) dose 5-FU7250mgkg
 1 PDTC. Regimens were chosen to model a single human dose and a
weekly schedule. The effects of another antioxidant N-acetylcysteine (NAC) were also investigated. Large intestinal crypts affect
apoptosis purely by p53-dependent mechanisms, whereas small intestinal crypts are able to initiate both p53-dependent and
-independent pathways following treatment with 5-FU. Pyrrolidinedithiocarbamate and NAC antagonised p53-dependent but
potentiated p53-independent apoptotic activity. Consequently, the proportion of surviving clonogens increased in the large but not in
the small intestine. Regional availability of p53-dependent and -independent apoptotic pathways in small and large intestine together
with separate modulation of these pathways by antioxidants explains the different regional enterotoxicity following 5-FU therapy.
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The dose-limiting enteric side effects of 5-fluorouracil (FU) are due
to a profuse wave of p53-driven apoptosis within normal intestinal
crypts accompanied by prolonged cell cycle arrest (Pritchard et al,
1998). The antioxidants pyrrolidinedithiocarbamate (PDTC) and
N-acetylcysteine (NAC) have been shown to enhance the activity of
5-FU against colorectal cancer cell lines independent of p53
function (Chinery et al, 1997; Bach et al, 2001). This is important
as p53 is frequently mutated in human cancer (Levine et al, 1991).
Although PDTC increased 5-FU-induced apoptosis within tumour
xenografts through the induction of p21
WAF1/CIP1 via CCAAT/
enhanced binding proteinb (Chinery et al, 1997), gastrointestinal
toxicity was unexpectedly reduced (Bach et al, 2000). Pyrrolidine-
dithiocarbamate significantly improved colonic clonogen survival
following the administration of 5-FU, whereas small intestinal
toxicity remained unchanged. This may be of biological signifi-
cance as 5-FU was a factor of 1log more toxic to large, compared
to small intestinal crypts. Similar relative toxicities have previously
been reported in humans (Milles et al, 1962). Reduced apoptosis
among colonic clonogens and prompt restoration of normal
mitotic activity appeared to account for the reduction in drug-
induced toxicity. Separate investigators have independently
demonstrated the ability of antioxidant compounds to ameliorate
the toxicity of 5-FU and a range of other chemotherapeutic
compounds, including oxaliplatin and paclitaxel (Alexandre et al,
2006b).
Reactive oxygen species (ROS) are unstable molecules derived
from normal mitochondrial metabolism. They set about obtaining
additional electrons from other molecules, such as DNA, proteins
and cell membranes. As a result of these interactions, donors may
incur structural damage that has led to the classical conception of
ROS as toxic metabolites. Antioxidants such as PDTC are electron
donors that have cytoprotective properties in disease states that
induce oxidative stress such as liver cirrhosis (Bruck et al, 2002)
and transplant reperfusion injury (Ross et al, 2000; Tsuchihashi
et al, 2003).
Good evidence now suggests that ROS also act as physiological
signalling molecules in a number of cellular processes including
proliferation and apoptosis. In this context, antioxidants such as
NAC exert an antiproliferative effect (Sekharam et al, 1998; Nargi
et al, 1999; Menon et al, 2003; Kang et al, 2004). This is of special
interest given that ROS production may be essential for the growth
of p53-deficient colorectal tumours (Sablina et al, 2005).
A third emerging view of antioxidants is as cellular markers
for apoptosis or necrosis following cytotoxic drug treatment. Revised 3 May 2006; accepted 17 May 2006
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sGeneration of H2O2 was consistently detected following treatment
with camptothecin, vinblastine, inostamycin and adriamycin in a
lung tumour cell line (Simizu et al, 1998). Scavenging of
H2O2 caused failure of apoptosis. Reactive oxygen species
generation has been demonstrated in a range of tumours 6–48h
after treatment with various anticancer agents (Ikeda et al,
1999; Huang et al, 2003; Fawcett et al, 2005; Rahmani et al,
2005). Indeed, the antitumour activity of paclitaxel in mice was
abolished by NAC as accumulation of H2O2 is an early and crucial
step for paclitaxel-induced cancer cell death (Alexandre et al,
2006a).
In this study, we sought to clarify the basis of differential small
and large bowel toxicity following combined treatment with PDTC
and 5-FU. We determined the availability of p53-dependent and
-independent apoptotic pathways in the small and large intestine
following 5-FU therapy and characterised the effect of PDTC upon
each pathway. We hypothesised that 5-FU would initiate activity in
both types of pathway but that separate modulation by PDTC at
this level might account for the differences in small and large
intestinal clonogenic stem cell survival. We measured p53-depen-
dent and -independent apoptosis in the small and large intestine of
p53 wild-type and knockout mice 6, 12, 24, 36, 48 and 72h after
high- or low-dose 5-FU therapy administered with or without
PDTC. We also determined the effects of a separate antioxidant,
NAC, upon 5-FU-induced apoptosis in the small and large
intestine.
MATERIALS AND METHODS
Animals
p53 wild-type (þ/þ) and p53 null ( / ) mice were from a colony
housed at the Paterson Institute for Cancer Research, Manchester,
UK derived from those generated by Donehower et al (1992). Mice
were aged 10–12 weeks, weighed approximately 25g and were kept
under a 12h light, 12h dark regimen, with free access to water and
the RM1-expanded diet (Special Diet Services, Waltham, Essex,
UK). Experiments were performed in accordance with the Animals
(Scientific Procedures) Act 1986 and revised UKCCCR guidelines
(1997).
Materials
5-Fluorouracil (Roche, Welwyn Garden City, UK) was adminis-
tered at 5mgml
 1 or 25mgml
 1 depending upon dose. Pyrroli-
dinedithiocarbamate (Sigma, Poole, UK) and NAC (Sigma, Poole,
UK) were freshly prepared in 0.9% (wt/vol) saline to a concentra-
tion of 6.25mg/0.2ml. Drug administration was by bolus
intraperitoneal injection with the first injection given at 0900
hours. Pyrrolidinedithiocarbamate or NAC were administered
15min before 5-FU. Optimum times for apoptotic assessment were
determined from previous studies (Pritchard et al, 1997; Pritchard
et al, 1998; Bach et al, 2000).
Effects of treatment upon apoptosis and mitosis in the
small and large intestine
Apoptosis and mitosis were assessed on a cell positional basis in
small and large intestinal crypts of p53 wild-type (þ/þ) and p53
null ( / ) mice 6, 12, 24, 36, 48 and 72h after administration
of (a) low-dose 5-FU (40mgkg
 1)7250mgkg
 1 PDTC and (b)
high-dose 5-FU (200mgkg
 1)7250mgkg
 1 PDTC. The effects of
another antioxidant NAC were determined in wild-type and null
mice 24 and 48h after administration of high-dose 5-FU
(200mgkg
 1)7200mgkg
 1 NAC.
The rationale for choosing 40mgkg
 1 5-FU is that it models a
single human dose (Pritchard et al, 1997). The LD50 for 5-FU in the
mouse is reported to be in the order of 450mgkg
 1 (Burns and
Beland, 1984). We have corroborated this figure for the p53
knockout mouse (Bach, 2003). The higher dose of 200mgkg
 1
5-FU is equivalent to 600mgm
 2 in this mouse, the exact concen-
tration of 5-FU employed for weekly combination schedules with
folinic acid in humans (Buroker et al, 1994). PDTC (250mgkg
 1 )
was the maximum tolerated as a single dose in previous experi-
ments utilising the BDF1 mouse (Bach et al, 2000), whereas
200mgkg
 1 NAC approximates to the clinical dose used in
humans (Prescott et al, 1989).
Mice were culled by cervical dislocation and intestinal
specimens promptly harvested. Six mice were utilised per experi-
mental group at each time point. Control animals, injected with
saline (0.2ml), were culled at the first time point. Small and large
intestine were prepared by methods described in detail previously
(Merritt et al, 1996). Apoptotic bodies and mitotic figures were
easily identified in haematoxylin- and eosin-stained sections by
their characteristic morphological appearance. We validated
morphological scoring of apoptosis against the terminal deoxy-
nucleotide transferase labelling (TUNEL) technique (ApopTag;
Oncor, Gaithersburg, MD, USA) (Bach, et al 2000). Statistically
valid results can be obtained by examining 200–300 half-crypt
sections from 4–6 mice, per group (Chwalinski and Potten, 1989).
Good cross-sections cut through the centre of a crypt’s long-
itudinal axis were examined using light microscopy (magnification
 640). Each crypt was considered as two-halves, divided along the
luminal axis with cells numbered sequentially from the crypt base.
Each position was scored as containing a normal cell, an apoptotic
cell (with one or more apoptotic bodies) or a mitotic figure. Data
were recorded using a PC microcomputer and software developed
at the Paterson Institute (Ijiri and Potten, 1983). Group treatment
was masked and a single observer (SPB) scored the slide sec-
tions. For each cell position, apoptotic and mitotic indices were
calculated as percentages. Data may be pooled over a series of
adjacent cell positions enabling comparisons to be made between
stem, presumed clonogenic and transitional cell zones within the
crypt. Results were analysed by a computer program developed at
the Paterson Institute based on the median test, a nonparametric
ranking test (Potten et al, 1990). P-values less than 0.001 were
considered significant.
Detection of p21
WAF1/CIP1
Intestinal samples were stained for p21
WAF1/CIP1; ab5 (Oncogene,
San Diego, CA, USA). Positive controls: irradiated mouse
enterocytes demonstrate nuclear staining. Negative controls:
substitution of nonimmune serum for primary antibody on a
second tissue section. Antigen retrieval was achieved by micro-
waving at high power (800W) for 20min. Primary antibody
concentrations of 1:200 were determined by serial dilutions.
Samples were processed using the avidin–biotin complex im-
munoperoxidase staining system (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), developed with diaminobenzidine and counter-
stained with thionine blue.
RESULTS
A five-fold increase in the dose of 5-FU administered from 40 to
200mgkg
 1 did not dramatically affect either the kinetics of onset
of apoptosis, the magnitude of the apoptotic response or the cell
positional incidence of apoptosis within small or large intestinal
crypts of wild-type animals. Dose escalation did considerably
extend the period of mitotic suppression. We shall describe results
obtained with 200mgkg
 1 in detail (data obtained following
administration of 40mgkg
 1 5-FU can be found in supplementary
files). Administration of PDTC as a single agent had no effect upon
apoptotic or mitotic indices (data not shown).
Enteral toxicity of 5-FU is modulated by PDTC
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Wild type 5-Fluorouracil increased apoptosis in p53 wild-type
large intestinal crypts with maximal values at 24h in the presumed
clonogenic stem cell compartment (cell positions 4–9) (Figure 1A
and B). Normal values were restored by 36h. Following coadminis-
tration of PDTC, significantly less apoptosis occurred at 24h
(Figure 1A and B). Clonogenic and transit cells were reprieved
(cell positions 6–13, Po0.001). N-acetylcysteine also inhibited
apoptosis at 24h (Table 1).
Administration of 5-FU produced a prompt decrease in the
mitotic index at 6h with a complete cessation of almost all
measured activity by 24h (Figures 2A). Recovery remained
incomplete at 72h. Coadministration of PDTC facilitated early
restoration of normal mitotic activity among clonogenic stem cells
at 72h (cell positions 4–9, Po0.001) (Figure 2B).
Null No significant elevation in apoptotic values occurred within
p53 null colonic crypts throughout the entire 72-h period following
5-FU7PDTC (Figure 1A) or NAC (Table 1). 5-Fluorouracil
decreased the mitotic index at 6h with only partial recovery by
72h (data not shown). The addition of PDTC did not significantly
alter these parameters.
Small intestine
Wild type 5-Fluorouracil alone increased apoptosis in p53 wild-
type small intestinal crypts with maximal values occurring between
12 and 24h within the clonogenic stem cell compartment
(Figure 3A and Supplementary data). The addition of PDTC
delayed the onset of apoptosis from 6 to 12h across all compart-
ments with peak values seen later between 24 and 36h (Figure 3A).
N-acetylcysteine increased apoptosis at 48h (Table 1).
5-Fluorouracil produced a prompt decrease in the mitotic index
at 6h with recovery at 72h (data not shown). Coadministration of
PDTC did not modulate these parameters (data not shown).
Null 5-Fluorouracil alone produced a modest elevation in apop-
tosis above baseline values at the 12, 24, 36 and 48h time points
(Figure 3A). The addition of PDTC delayed the onset of apoptosis
beyond 12h (Figure 3A), and by 48h, peak values were double
than those observed with 5-FU alone throughout the whole crypt
axis (cell positions 3–18, Po0.001) (Figure 3B). Similarly, elevated
peak values were seen following NAC (Table 1). Peak values
equated to those measured in similarly treated wild-type animals.
This late rise in apoptosis within p53 null small intestinal crypts
was also seen following 40mgkg
 1 5-FUþPDTC at 36h; cell
positions 3–13 (Po0.001) (Supplementary data).
5-Fluorouracil produced a prompt decrease in the mitotic index
at 6h with complete cessation of almost all measured activity up to
72h at which point recovery occurred (data not shown).
Coadministration of PDTC did not modulate these parameters
(data not shown).
p21
WAF1/CIP1 expression in small intestinal crypts
No p21
WAF1/CIP1 expression occurred in controls (saline injection)
(data not shown). Elevated nuclear expression of the p21
WAF1/CIP1
protein occurred within the transit cell population 6h after
administration of PDTC75-FU (data not shown) with maximal
staining intensity in surviving cells at 48h (Figure 4A), resolving
by 72h. Nuclear staining was determined on a cell positional basis
at 48h with high labelling indices among animals treated with
5-FU7PDTC concentrated about cell positions 6–10 and no
statistically significant difference between groups (data not
shown).
Despite achieving high levels of apoptosis within small intestinal
crypts of p53 null mice treated with PDTC/5-FU, no significant
induction of p21
WAF1/CIP1 occurred at any time point (Figure 4B).
DISCUSSION
Large intestinal toxicity
In p53 wild-type large intestine, administration of 5-FU alone
produced an isolated apoptotic peak in all crypt compartments at
24h (Figure 1A). Coadministration of PDTC and NAC significantly
reduced the number of apoptotic events measured at 24h, espe-
cially among clonogenic stem cells (Figure 1B). Apoptotic activity
in p53 null colon remained at baseline values throughout the 72h
period regardless of whether PDTC or NAC were also administered
(Figure 1A). Pyrrolidinedithiocarbamate facilitated early mitotic
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Figure 1 Large intestinal apoptosis. (A) Time course of mean apoptotic
index is displayed for the whole crypt (cell positions 1–18) following
200mgkg
 1 5-FU alone7250mgkg
 1 PDTC in p53 wild-type and p53
null mice. Six animals per group at each time point (6, 12, 24, 36, 48 and
72h) counting 50 half-crypts per mouse. (B) Apoptotic index is displayed
for each crypt cell position 24h after the administration of treatment in p53
wild-type mice. Chevron indicates cell positions over which a significant
difference was detected between treatments (Po0.001, PC crypts).
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recovery at this time point remained incomplete in mice treated
with 5-FU alone (Figure 2B). In summary, the murine large
intestine initiated only p53-driven apoptosis in response to 5-FU.
These events were inhibited by both PDTC and NAC producing a
marked improvement in the proportion of surviving clonogens.
Mitotic recovery was subsequently enhanced and tissue regenera-
tion as measured by the crypt survival assay improved (Bach et al,
2000).
Small intestinal toxicity
In p53 wild-type small intestine, 5-FU initiated a rise in apoptosis
within 6h; peak values occurred between 12 and 24h (Figure 3A).
Pyrrolidinedithiocarbamate did not simply antagonise maximal
apoptotic values as occurred in the large intestine. At 6 and 12h,
PDTC reduced apoptosis among stem, presumed clonogenic and
transit cell populations (Figure 3A and Supplementary data). The
situation was subsequently reversed as PDTC then led to higher
apoptotic values compared to 5-FU alone at 24 and 36h
(Figure 3A). Higher apoptotic values were observed at 48h
following administration of 5-FU and NAC (Table 1). No difference
in mitotic recovery was seen in the wild-type small intestine
following PDTC. A combination of reduced clonogen availability
and prolonged p21
WAF1/CIP1 expression will limit mitotic recovery
under these circumstances (Pritchard et al, 1998).
In contrast to results from p53 null large bowel, increased
apoptotic activity was recorded in the p53 null small intestine
following 5-FU administration. It was also notable that dose
escalation from 40 to 200mgkg
 1 5-FU produced a markedly
increased the magnitude and duration of apoptotic activity
(Supplementary data). At 200mgkg
 1 5-FU, peak apoptotic values
in the p53 null small intestine approached those seen in wild
types, although these values occurred somewhat later in null
littermates, between 24 and 48h (Figure 3A). Pyrrolidinedithio-
carbamate and NAC significantly augmented peak levels of p53-
independent apoptosis at 36 and 48h by a factor of two to three
(Figure 3A and B and Table 1). Despite finding abundant p21
WAF1/
CIP1 expression within wild-type small intestinal crypts at these
time points (Figure 4A), no expression was detected within p53
null enterocytes (Figure 4B). This is in contrast to a previous
report utilising PDTC and 5-FU therapy in p53 null colorectal
cancer cell lines where PDTC was found to induce apoptosis
via p21
WAF1/CIP1 (Chinery et al, 1997). In our model, augmenta-
tion of p53-independent apoptosis by PDTC does not result from
modulation of p21
WAF1/CIP1. Administration of PDTC did not alter
the duration of cell cycle arrest as mitotic recovery occurred
simultaneously for both groups at 72h (data not shown).
It appears that small intestinal crypts can affect programmed
cell death by both p53-dependent and -independent pathways
following treatment with the antimetabolite 5-FU. We are unable to
specify what proportion of late apoptotic events are mediated by
p53-dependent and -independent pathways respectfully in the
wild-type mouse, although it is clear from their null littermates
that appreciable p53-independent activity is possible and that this
activity is upregulated by coadministration of PDTC or NAC. As a
result, PDTC does not significantly modulate the number of
surviving clonogens in the small intestine; mitotic recovery is not
Table 1 Large and small intestinal apoptotic activity in p53 wild-type and
p53 null mice following high dose 5-FU (200mgkg
 1)7NAC
(200mgkg
 1)
Apoptotic index (%)
Large intestine Small intestine
p53 Time (h) 5-FU 5-FU+NAC 5-FU 5-FU+NAC
Wild-type Control 0.21 0.21 0.22 0.22
24 15.05 6.40
a 7.80 8.21
48 1.10 0.33 4.39 6.20
a
Null Control 0.09 0.09 0.18 0.18
24 1.11 0.72 5.12 6.68
48 0.48 0.42 5.39 10.93
a
Apoptotic indices are expressed for the crypt as a whole over cell positions 1–18. Six
animals were used in each group, counting 50 half-crypts per mouse. Control values
(saline injection) are shown in ‘normal typeface’ as are treatment indices that do not
significantly differ from these baseline values (P40.001, PC crypts). Treatment indices
outside control values are displayed in bold (Po0.001, PC crypts).
aA significant
difference between 5-FU and 5-FU/NAC treatments at a specific time point
(Po0.001, PC crypts).
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Figure 2 Large intestinal mitosis. (A) Time course of mean mitotic index
is displayed for the whole crypt (cell positions 1–18) following 200mgkg
 1
5-FU alone7250mgkg
 1 PDTC in p53 wild-type and p53 null mice. Six
animals per group at each time point (6, 12, 24, 36, 48 and 72h) counting
50 half-crypts per mouse. (B) Mitotic index is displayed for each crypt cell
position 72h after the administration of treatment in p53 wild-type mice.
Chevron indicates cell positions over which a significant difference was
detected between treatments (Po0.001, PC crypts).
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sexpedited and consequently this agent has no impact upon small
intestinal crypt survival (Bach et al, 2000).
Molecular control of intestinal toxicity
The mechanism by which 5-FU induces apoptosis in the normal
intestine involves initial interference of RNA signalling pathways
followed by activation of the p53 pathway (Pritchard et al, 1997;
Bunz et al, 1999; Longley et al, 2002). Several transcriptional
targets of p53 are genes whose products generate ROS (Polyak
et al, 1997; Macip et al, 2003). It is hypothesised that these
products contribute towards p53-mediated apoptosis. In addition,
a set of 5-FU-dependent, p53-inducible genes, continue to be
defined. In the context of our study, the most interesting of these is
a gene coding for mitochondrial ferredoxin reductase (FDXR).
Ferredoxin reductase may represent a mechanism by which ROS
are generated. Reactive oxygen species cause permeabilisation of
the mitochondrial membrane with release of the proapoptotic
proteins cytochrome c and apaf-1 (Kroemer and Reed, 2000).
Ferredoxin reductase expression following 5-FU exposure in a
p53þ/þ CRC cell line correlated with increased oxidative stress
and apoptosis (Hwang et al, 2001). Increasing levels of FDXR
independent of 5-FU therapy did not result in increased apop-
tosis (Liu and Chen, 2002). Ferredoxin reductase contains a p53-
responsive element in its promoter region (Liu and Chen, 2002).
The effects of 5-FU were abrogated in FDXR knockout clones and
pharmacological inhibition of 5-FU activity was achieved by the
use of two antioxidant agents, ubiquinol and a mitochondrial-
targeted derivative mitoQ (Hwang et al, 2001). MitoQ was shown
to prevent the reduced clonogenicity associated with 5-FU
treatment in vitro in accordance with our results using PDTC
and 5-FU in vivo (Bach et al, 2000). A mechanism therefore exists
to explain the observed reduction in p53-driven apoptosis
following the addition of PDTC or NAC to 5-FU therapy.
Apoptosis does not feature in the response of p53 null colonic
enterocytes to 5-FU (Figure 1A). Similar effects have been reported
in this model following radiation treatment (Merritt et al, 1994)
and in a colorectal cancer cell line subject to 5-FU (Bunz et al,
1999). Interestingly, the five most highly transcriptionally activated
genes in a CRC cell line following 5-FU exposure all possess
putative p53 response elements (Maxwell et al, 2003). It seems
likely that the unspecified p53-independent apoptotic mechanism
present within small intestinal enterocytes and augmented by
PDTC is simply absent from colonocytes.
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Figure 3 Small intestinal apoptosis. (A) Time course of mean apoptotic
index is displayed for the whole crypt (cell positions 1–18) following
200mgkg
 1 5-FU alone7250mgkg
 1 PDTC in p53 wild-type and p53
null mice. Six animals per group at each time point (6, 12, 24, 36, 48 and
72h) counting 50 half-crypts per mouse. (B) Apoptotic index is displayed
for each crypt cell position 48h after the administration of treatment in p53
null mice. Chevron indicates cell positions over which a significant
difference was detected between treatments (Po0.001, PC crypts).
Figure 4 Immunohistochemical sections from (A) p53þ/þ ( 400)
and (B) p53 /  mouse small intestinal crypts ( 500) stained for
p21
WAF1 48h following 200mgkg
 1 5-FU and 250mgkg
 1 PDTC.
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apoptosis purely by p53-dependent mechanisms, whereas small
intestinal crypts are able to initiate both p53-dependent and -
independent pathways following treatment with 5-FU. Pyrrolidi-
nedithiocarbamate and NAC antagonised p53-dependent but
potentiated p53-independent apoptotic activity. Consequently,
the proportion of surviving clonogens increased in the large but
not in the small intestine and early recovery of normal mitotic
activity occurred only in the large bowel. Functional outcome at a
tissue level is measured in terms of improved large bowel crypt
regeneration 6 days after an enterotoxic schedule of 5-FU (Bach
et al, 2000). Despite the fact that PDTC modulates murine large
bowel toxicity to 5-FU in isolation, this finding may still be of
clinical relevance. We have previously shown that 5-FU is relatively
more toxic (by a factor of one log) to large as opposed to small
intestinal crypts in our mouse model (Bach et al, 2000). Evidence
exists to suggest that this situation may also be replicated in
humans (Milles et al, 1962). Pyrrolidinedithiocarbamate or NAC in
addition to other agents with similar biochemical properties may
therefore reduce the p53-driven apoptotic events that mediate 5-
FU-related drug-induced toxicity. p53-independent apoptotic
pathways that are likely to be recruited therapeutically were not
similarly affected. The potential to reduce diarrhoea during
multimodality neoadjuvant therapy for rectal cancer should also
be examined further.
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